{"url":"https://newsforagent.com/news/2026-11-11/anthropic-six-biotech-ai-drug-discovery","markdown_url":"https://newsforagent.com/news/2026-11-11/anthropic-six-biotech-ai-drug-discovery.md","title":"Anthropic Partners With Six Biotechs on AI Drug Discovery","headline":"Anthropic Teams With Bristol Myers Squibb, BigHat and Others to Speed Drug Discovery","description":"Anthropic has partnered with six organisations, including Bristol Myers Squibb and BigHat Biosciences, to apply Claude to drug discovery.","section":"Partnerships","published_at":"2026-11-11T15:48:16+00:00","modified_at":"2026-11-11T15:48:16+00:00","author":"News Desk","key_takeaways":["Anthropic said it has partnered with six organisations, including Bristol Myers Squibb, Generate Biomedicines and BigHat Biosciences, to explore AI in drug development.","A Generate Biomedicines CAR T-cell redesign made with Claude Code was about 70 per cent shorter and helped immune cells produce roughly 10 times more receptors in lab tests.","Anthropic said one of its muscular dystrophy drug candidates could enter human clinical trials as early as late 2028."],"companies":[{"name":"Anthropic","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000002/anthropic","website":"https://www.anthropic.com"},{"name":"BigHat Biosciences","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00005r4/bighat-biosciences","website":"http://www.bighatbio.com"},{"name":"Enveda Biosciences","is_primary":false,"profile_url":"https://akta.pro/company-profiles/00000kk/enveda-biosciences","website":"https://enveda.com"}],"source":{"publisher":"The Times of India","title":"'Cancer will be history in 10 years': Anthropic CEO Dario Amodei's big AI-powered promise","url":"https://timesofindia.indiatimes.com/world/rest-of-world/cancer-will-be-history-in-10-years-anthropic-ceo-dario-amodeis-big-ai-powered-promise/articleshow/135741699.cms"},"other_sources":[],"tags":["Partnerships","Anthropic","BigHat Biosciences","Enveda Biosciences"],"body_markdown":"[Anthropic](https://akta.pro/company-profiles/0000002/anthropic) said it has partnered with six organisations, including Bristol Myers Squibb, Generate Biomedicines and BigHat Biosciences, to explore how artificial intelligence can speed up stages of developing new medicines. [The Times of India](https://timesofindia.indiatimes.com/world/rest-of-world/cancer-will-be-history-in-10-years-anthropic-ceo-dario-amodeis-big-ai-powered-promise/articleshow/135741699.cms) reported the partnerships on November 11, 2026, alongside work on cancer, food allergies and rare diseases.\n\n## How the Six Biotech Partnerships Work\n\nAnthropic, the company behind the Claude chatbot, said the collaborations cover different points in the drug development process. One project with Generate Biomedicines adapts CAR T-cell therapy, traditionally used against blood cancers, to treat solid tumours. Six Generate scientists used Claude Code to propose a redesigned version of a section of the therapy's genetic instructions, and the new design was about 70 per cent shorter than the standard version. Laboratory tests found it helped immune cells produce roughly 10 times more receptors, improved their ability to kill tumour cells and kept them active for longer.\n\nA second collaboration, with [BigHat Biosciences](https://akta.pro/company-profiles/00005r4/bighat-biosciences), focused on improving two potential drug candidates, including one designed to target cancer cells. After testing around 1,010 variations, researchers found the best version bound to its target more than 10 times as tightly as the original. BigHat said in September 2026 that it had closed a $75 million Series C financing co-led by DFJ Growth and Premji Invest, bringing total funding to $223 million, and that the proceeds would support its AI-designed therapeutics pipeline and its protein design platform, according to FinancialContent Business Page.\n\nAnthropic also said its work with Divergence Labs generated around 35,000 antibody designs in approximately a month for a potential food allergy treatment. Its collaboration with [Enveda Biosciences](https://akta.pro/company-profiles/00000kk/enveda-biosciences) reduced the time required for human review of manufacturing documents by 89 per cent.\n\n## Anthropic's Own Drug Programmes\n\nAnthropic has started its own drug discovery programmes, including research into rare childhood forms of muscular dystrophy. The company cautioned that much of this research remains at the preclinical stage, meaning the potential treatments have not reached human trials. It said one of its muscular dystrophy drug candidates could be ready to enter human clinical trials as early as late 2028, provided the promising results continue to hold up.\n\n## Anthropic's Funding and Revenue Records\n\nAnthropic's post-Series G funding round valued the company at $380 billion, according to akta.pro [company records](https://akta.pro/company-data). The Series G round was $30 billion, led by GIC and Coatue, with participation from Microsoft, NVIDIA, D.E. Shaw Ventures, Dragoneer, Founders Fund, ICONIQ and MGX. The same records show revenue grew from a $14 billion run-rate in February 2026 to a $47 billion annualized run-rate by July 2026.\n\n## Earlier Anthropic Announcements\n\nOn November 11, 2026, LawVu announced that its LegalOS now connects five AI tools, including Claude, via an MCP Server without custom development, exposing over 50 actions, PR Newswire reported. Anthropic's revised S-1 filing showed it added over $10 billion in minimum compute commitments to Microsoft and Google ahead of its IPO, with the Microsoft obligation at least $44.9 billion and Google at $121.3 billion, both largely non-cancelable, according to Crypto Briefing. Gadgets 360 reported that Anthropic CEO Dario Amodei said cancer, Alzheimer's, heart disease and mental illness would be relics in less than a decade, citing AI's potential to accelerate drug discovery.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}